COVID-19 vaccine effectiveness
(Randomized evidence)

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04651790
Sinovac Research and Development Co., Ltd
Bueno S, Clin Infect Dis, 2021 ()

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 3 mcg D0/14

Adjuvant D0/14

RCT
Phase 3
Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. N=434
Some concerns
Details

Full description

NCT04508075 ; INA-WXFM0YX
Sinovac Research and Development Co., Ltd
Fadlyana E, Vaccine, 2021 ()

Full text
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Healthy adults aged 18 - 59 years, seropositive and seronegative, at a single center in Indonesia N=1620
Some concerns
Details

Full description

NCT04551547
Sinovac Research and Development Co., Ltd
Han B, SSRN, 2021 ()

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 1.5 mcg D0/28

CoronaVac 6 mcg D0/14

Adjuvant

RCT
Phase 1/2
Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. N=552
Low
Details

Full description

NCT04456595
Sinovac Research and Development Co., Ltd
Palacios R, SSRN, 2021 ()
PROFISCOV

Full text
Commentary
Inactivated virus

CoronaVac 3mcg D0/14

Adjuvant D0/14

RCT
Phase 3
Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. N=12408
Some concerns
Details

Full description

NCT04582344
Sinovac Research and Development Co., Ltd
Tanriover M, Lancet , 2021 ()

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Adjuvant

RCT
Phase 3
Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey N=10218
Some concerns
Details

Full description

NCT04383574
Sinovac Research and Development Co., Ltd
Wu Z, Lancet Infect Dis, 2021 ()

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac, 1.5mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28

CoronaVac, 3mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28

CoronaVac, 6mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28

Adjuvant (Aluminum hydroxide)

RCT
Phase 1/2
Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China N=422
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Zhang Y, Lancet Infect Dis, 2020 ()

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac 3 mcg D0/14

CoronaVac 6 mcg D0/14

CoronaVac 3 mcg D0/28

CoronaVac 6 mcg D0/28

Adjuvant

RCT
Phase 2
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=600
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Zhang Y, Lancet Infect Dis, 2020 ()

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac 6 mcg D0/28

CoronaVac 3 mcg D0/28

CoronaVac 6 mcg D0/14

CoronaVac 3 mcg D0/14

Adjuvant

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=144
Some concerns
Details

Full description